Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.